Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy

Author(s): Josephine M. Forbes, Vicki Thallas-Bonke, Mark E. Cooper, Merlin C. Thomas

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 27 , 2004

Become EABM
Become Reviewer
Call for Editor


Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.

Keywords: advanced glycation end products, diabetes, diabetic nephropathy, age inhibitor, cross-link breaker, cml, pentosidine, rage

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [3361 - 3372]
Pages: 12
DOI: 10.2174/1381612043383151
Price: $65

Article Metrics

PDF: 4